structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET | Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023 19:41 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...